{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:19:22Z","timestamp":1789154362149,"version":"build-2803163510"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"18","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>This case series explores the use of thrombin time (TT) to transition 2 patients from dabigatran to unfractionated heparin (UFH) in the setting of acute kidney injury (AKI) and coagulopathy concerning for dabigatran accumulation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Serial TT monitoring was employed until the value began to trend below 120 seconds, indicating ongoing drug clearance, at which point UFH was initiated. Patient 1 experienced rectal bleeding following initiation of UFH, while patient 2 experienced hemoglobin drops without an apparent bleeding source. No thrombotic events occurred during either hospitalization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Individualized management remains paramount to balance bleeding and thrombotic risk based on patient-specific factors. Further research is warranted to validate the safety and efficacy of a TT-guided transition strategy and optimize protocols for hospitalized patients transitioning from dabigatran to UFH.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf059","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:16:24Z","timestamp":1743120984000},"page":"1022-1025","source":"Crossref","is-referenced-by-count":1,"title":["Use of thrombin time to transition from dabigatran to intravenous unfractionated heparin in patients with acute kidney injury"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-1477","authenticated-orcid":false,"given":"Donna","family":"Barakeh","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Houston Methodist Hospital , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R","family":"Donahue","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Houston Methodist Hospital , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Sabawi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Houston Methodist Willowbrook Hospital , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Dreucean","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Houston Methodist Hospital , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"issue":"13","key":"2025090819570605000_CIT0001","doi-asserted-by":"crossref","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"13","key":"2025090819570605000_CIT0002","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.110.004424","article-title":"Dabigatran etexilate: a new oral thrombin inhibitor","volume":"123","author":"Hankey","year":"2011","journal-title":"Circulation"},{"key":"2025090819570605000_CIT0003","author":"Pradaxa (dabigatran etexilate mesylate)","year":"2011"},{"issue":"10","key":"2025090819570605000_CIT0004","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/phar.2726","article-title":"Direct oral to parenteral anticoagulant transitions: role of factor Xa inhibitor-specific anti-Xa concentrations","volume":"42","author":"Dinunno","year":"2022","journal-title":"Pharmacotherapy"},{"key":"2025090819570605000_CIT0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jcph.1694","article-title":"Direct oral to parenteral anticoagulants: strategies for inpatient transition","volume":"61","author":"Lopez","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"2025090819570605000_CIT0006","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/ajhp\/zxz013","article-title":"Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion","volume":"76","author":"Zochert","year":"2019","journal-title":"Am J Health-Syst Pharm"},{"issue":"6","key":"2025090819570605000_CIT0007","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate \u2014 a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"issue":"3","key":"2025090819570605000_CIT0008","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/bcp.12366","article-title":"Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran","volume":"78","author":"Chin","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2025090819570605000_CIT0009","author":"STA-Thrombin Time","year":"2018"},{"key":"2025090819570605000_CIT0010","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/B978-0-12-815499-1.00026-0","article-title":"Hemostasis","volume-title":"Contemporary Practice in Clinical Chemistry","author":"Campbell","year":"2020","edition":"4th ed"},{"key":"2025090819570605000_CIT0011","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/B978-0-323-44942-7.00102-3","article-title":"Bleeding and hemostasis in acute renal failure","volume-title":"Critical Care Nephrology","author":"Podest\u00e0","year":"2019","edition":"3rd ed"},{"issue":"11","key":"2025090819570605000_CIT0012","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2014.05.065","article-title":"Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants","volume":"64","author":"Cuker","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2025090819570605000_CIT0013","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11239-015-1282-7","article-title":"Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication","volume":"41","author":"Cuker","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"7","key":"2025090819570605000_CIT0014","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2146\/ajhp160168","article-title":"Successful use of laboratory monitoring to facilitate an invasive procedure for a patient treated with dabigatran","volume":"74","author":"Byron","year":"2017","journal-title":"Am J Health-Syst Pharm"},{"issue":"11","key":"2025090819570605000_CIT0015","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1111\/jth.13486","article-title":"Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter\/multiplatform study","volume":"14","author":"Testa","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"15","key":"2025090819570605000_CIT0016","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/ajhp\/zxab182","article-title":"Thromboelastography utilization for dabigatran reversal in a patient with acute kidney injury","volume":"78","author":"Gilbert","year":"2021","journal-title":"Am J Health-Syst Pharm"},{"issue":"4","key":"2025090819570605000_CIT0017","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf059\/62593199\/zxaf059.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/18\/1022\/62593199\/zxaf059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/18\/1022\/62593199\/zxaf059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T23:57:38Z","timestamp":1757375858000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/18\/1022\/8092846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":17,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,3,25]]},"published-print":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf059","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,15]]},"published":{"date-parts":[[2025,3,25]]}}}